Targeted genome editing by engineered endonucleases allows the precise introduction of gene deletions and substitutions into the target genome. In 'Bench to Bedside', Keith Joung and his colleagues discuss how genome-editing technologies could be applied to engineer disease-associated somatic variation into human cell lines and disease models. This would allow the functional interpretation of such variants, which could then be applied to molecular diagnostics in the clinic. In 'Bedside to Bench', Angelo Lombardo and Luigi Naldini consider the potential applications of genome editing in the clinic, in which engineered endonucleases have been shown to be safe. Endonucleases could replace disease-associated genes with wild-type versions or be used to delete genes encoding receptors essential to viral host entry to prevent infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).
Holt, N. et al. Nat. Biotechnol. 28, 839–847 (2010).
Genovese, P. et al. Nature 510, 235–240 (2014).
Ciccia, A. & Elledge, S.J. Mol. Cell 40, 179–204 (2010).
Liu, R. et al. Cell 86, 367–377 (1996).
Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).
Lombardo, A. et al. Nat. Biotechnol. 25, 1298–1306 (2007).
Lombardo, A. et al. Nat. Methods 8, 861–869 (2011).
Fischer, A., Hacein-Bey-Abina, S. & Cavazzana-Calvo, M. Gene 525, 170–173 (2013).
Beerman, I., Seita, J., Inlay, M.A., Weissman, I.L. & Rossi, D.J. Cell Stem Cell 15, 37–50 (2014).
Gabriel, R. et al. Nat. Biotechnol. 29, 816–823 (2011).
Kim, H. & Kim, J.S. Nat. Rev. Genet. 15, 321–334 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they receive some research funding from Sangamo BioSciences to perform targeted genome editing with ZFNs and that they are inventors on filed patent applications on targeted genome editing.
Rights and permissions
About this article
Cite this article
Lombardo, A., Naldini, L. Genome Editing: A Tool For Research and Therapy: Targeted genome editing hits the clinic. Nat Med 20, 1101–1103 (2014). https://doi.org/10.1038/nm.3721
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3721
This article is cited by
-
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS
Molecular Therapy - Methods & Clinical Development (2016)